EN | TR
E-ISSN: 3061-9947
Evaluation of Effect and Side Effects of Pemetrexed in Patients with Advanced-Stage Lung Adenocarcinoma
PDF
Cite
Share
Request
Original Article
VOLUME: 55 ISSUE: 1
P: 25-33
2022

Evaluation of Effect and Side Effects of Pemetrexed in Patients with Advanced-Stage Lung Adenocarcinoma

Acta Haematol Oncol Turc 2022;55(1):25-33
DOI: 10.5505/aot.2022.23500
Serkan Gökçay 1
Elif Atag 2
1. Mehmet Akif İnan Training And Education Hospital, Medical Oncology, Sanlıurfa
2. Haydarpasa Numune Training And Education Hospital, Medical Oncology, Istanbul
3.
No information available.
No information available
Received Date: 2021-07-13T15:32:22
Accepted Date: 2022-03-31T17:36:18
PDF
Cite
Share
Request

Abstract

INTRODUCTION

The purpose of this study was to evaluate the efficacy and dose-limiting side effects of pemetrexed use in patients with advanced-stage non-small-cell lung adenocarcinoma.

METHODS

This study was conducted retrospectively by examining the files of patients who received treatment between 2017 and 2019. The dose-limiting side effects of the patients were evaluated by looking at the blood tests taken before each cycle and the notes in their files. All toxicities were classified by using the Common Terminology Criteria for Adverse Events.

RESULTS

The most common dose-limiting side effect was neutropenia, which developed in 50% of the patients. Side effects that affecting all blood series were observed in 28,1% of patients. The incidence of side effects of platinum given with pemetrexed was similar. Longer median survival was statistically correlated within patients receiving pemetrexed + platinum combination chemotherapy in the second and subsequent lines (p < 0.05).

DISCUSSION AND CONCLUSION

Pemetrexed is an easily tolerated and effective chemotherapy agent in advanced-stage non-small-cell lung carcinomas.